Swiss medical device company CeQur has raised $120 million in funding to expand its innovative approach to insulin delivery for diabetes patients. The financing will enable the company to scale up the commercial reach of CeQur Simplicity, its four-day wearable insulin delivery device. With diabetes management often requiring frequent injections, this device seeks to minimize the burden of mealtime insulin dosing, offering a discreet and injection-free alternative. The funding will also support the growth of CeQur’s sales and clinical teams in a bid to improve accessibility for patients.
What makes CeQur Simplicity stand out?
CeQur Simplicity is designed to provide a simple and convenient insulin delivery method, suited for rapid-acting bolus dosing across a four-day period. The patch can hold up to 200 units of insulin, eliminating the need for an average of 12 injections over its duration. Clinical studies have revealed that nearly 90% of patients reported improved adherence to their insulin treatment when switching to CeQur Simplicity compared to multiple daily injections. Additionally, the device has been shown to enhance glycemic control, including better A1C levels and time-in-range outcomes.
How accessible is the device for patients?
Over 6,000 patients currently use the CeQur Simplicity device, and the company has achieved significant progress in its insurance coverage. With agreements in place with Medicare Part D and state Medicaid programs, more than 80% of claims are reimbursed. Two-thirds of commercially insured patients also have access to the device through pharmacy formularies, with an average monthly copayment of under $45. Such initiatives aim to make the device affordable and widely accessible.
In earlier updates, CeQur had faced challenges in scaling its operations, but the company recently completed the qualification of its 40,000 sq. ft. cleanroom facility in late 2024. This facility will begin commercial production in 2025, a milestone that reflects the company’s readiness to meet growing demand. Earlier reports also highlighted CeQur’s focus on simplifying diabetes care, but this recent funding round marks a pivotal moment in its commercial strategy.
Brad Paddock, CeQur’s President and CEO, expressed gratitude for investor confidence, stating,
“We are grateful for the support of our investors as we accelerate our mission to transform diabetes care.”
The financial backing will further solidify CeQur’s place in the diabetes management market, enabling it to reach more patients and expand its impact.
Looking ahead, CeQur is poised to address the burden of diabetes management with its wearable technology. While the product shows promise, its success will depend on patient adoption, competitive positioning, and ongoing clinical results. For individuals with diabetes, solutions like CeQur Simplicity could represent a significant improvement in quality of life and ease of treatment. The company’s focus on affordability, backed by insurance coverage, might also play a crucial role in achieving widespread utilization.
